Small molecule compound SorB3 for targeted degradation of FLT3 protein and synthesis method and application thereof

By designing a small molecule compound SorB3 that targets the degradation of FLT3 protein, combining sorafenib and E3 ligase ligand, PROTAC technology promotes the degradation of FLT3 protein, solving the problems of resistance and side effects of existing FLT3 targeted therapeutic agents. Effective inhibition and safety improvement of FLT3 mutant leukemia has been achieved.

CN119019486APending Publication Date: 2024-11-26SUZHOU HEALTH COLLEGE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411126264.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing FLT3-targeted therapeutic agents are prone to drug resistance in clinical use, and have great side effects, and lack effective therapeutic methods to overcome drug resistance and reduce side effects.

Method used

SorB3, a small molecule compound that targets the degradation of FLT3 protein, was designed to target the degradation of FLT3 protein by combining sorafenib and E3 ligase ligand, and using PROTAC technology to promote the degradation of FLT3 protein, developed a new FLT3 targeting inhibitor, which can Effectively reduce FLT3 protein expression levels and overcome drug resistance.

Benefits of technology

SorB3 can dose-dependently reduce FLT3 protein expression, has good selectivity for FLT3 mutant AmL cells, effectively inhibit FLT3 kinase activity, overcome sorafenib resistance, and has lower toxicity to normal cells and tissues than SorB Rafenib, demonstrates the potential to combat FLT3 mutant leukemia and reduces side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019486A_ABST
    Figure CN119019486A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicine, and particularly relates to a small molecule compound SorB3 for targeted degradation of FLT3 protein and a synthesis method and application thereof. According to the invention, BOC amino polyethylene glycol carboxyl is taken as a PROTAC linker, an N end point outside an active pocket is taken as a binding site of the linker and sorafenib, an E3 ligase ligand 1 is taken as an E3 ligase ligand, and finally, the E3 ubiquitin ligase ligand 1 is connected on the basis of a sorafenib docking link molecule to complete the design of the SorB3 molecule. The FLT3 target protein is effectively linked to the E3 ligase ligand, the potential of resisting FLT3 mutant leukemia is shown, a novel and more effective FLT3 target inhibitor is created, development of drug resistance can be effectively prevented or delayed, alkali has few side effects, and a new thought is provided for limitation faced by existing treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a small molecule compound SorB3 targeted at degrading FLT3 protein, and a synthesis method and application thereof. Background Art

[0002] Acute myeloid leukemia (AmL) is a highly diverse hematological malignancy that causes proliferation of bone marrow primitive cells with blockade of expansion and differentiation, leading to failure of normal hematopoiesis and endangering life safety. AmL accounts for 80% of acute leukemia, and more than 80,000 AmL patients die each year worldwide. With the development of research on the etiology and pathogenesis of blood diseases, its treatment has evolved from traditional radiotherapy and chemotherapy, blood component support therapy, etc. to a combined treatment system consisting of radiotherapy and chemotherapy, molecular targeted therapy, immune cells, and transplantation. AmL treatment usually adopts a holistic treatment plan. Before treatment, a complete treatment plan should be formulated according to the condition and prognosis, and it should be continuously revised and improved during treatment to achieve the best therapeutic effect.

[0003] FLT3 (Fms-like tyrosine kinase, FMS-like tyrosine kinase 3) is a member of the receptor tyrosine kinase class III subfamily. The impact of FLT3-TKD mutation on the prognosis of AmI patients is still controversial, but some FLT3-ITD-positive AmL patients develop FLT3-TKD mutations after previous targeted therapy, leading to acquired drug resistance and treatment failure, which brings great challenges to the subsequent treatment of AmL. FLT3 can also phosphorylate B-catenin, which helps cell transformation and increases the production of reactive oxygen species, leading to genomic DNA instability. FLT3-ITD mutations can be seen in 30% of AmL patients, accounting for about 25% to 35% of the total incidence of AmL in adults and 12% of the total incidence of AmL in children. Compared with mutation-negative patients, FLT3-ITD-positive AmL patients have a worse response to induction chemotherapy, a higher relapse rate, and a shorter relapse-free survival (RFS) and overall survival (OS) time. The impact of FLT3-TKD mutation on the prognosis of AmL patients is still controversial. However, some FLT3-ITD-positive AmL patients develop FLT3-TKD mutation after previous targeted therapy, leading to acquired drug resistance and treatment failure, which poses a huge challenge to the subsequent treatment of AmL.

[0004] Since FLT3 mutation is the most common molecular mutation in AmL, and patients with mutation have a poor prognosis under traditional treatment strategies, FLT3 is one of the most attractive therapeutic targets for AmL treatment, hoping to improve the prognosis of this type of AmL. At present, FLT3 inhibitors have initially achieved positive clinical efficacy in the treatment of acute myeloid leukemia, and many FLT3 signaling inhibitors have been identified and are undergoing clinical trials. The development of FLT3-targeted small molecule inhibitors such as midostaurin, quizartinib, and gilteritinib has not only prolonged the median survival rate of newly diagnosed FLT3 AmL patients, but more importantly, it has increased the treatment response rate of refractory / relapsed FLT3 AmL from 10% to 20% to 50% to 66%.

[0005] However, since drugs often cause adverse reactions such as drug tolerance during clinical use, and the mechanisms of drug resistance are complex and diverse, there is still a lack of effective treatments in clinical practice to overcome drug resistance. Summary of the invention

[0006] In order to solve the above technical problems, the present invention provides a small molecule compound SorB3 for targeted degradation of FLT3 protein and its synthesis method and application to solve the problems existing in the above prior art. The small molecule compound SorB3 provided by the present invention combines sorafenib with E3 ligase ligand, connected by a linker of 13 carbon atoms, thereby promoting the effective degradation of FLT3 protein. The present invention effectively links the FLT3 target protein to the E3 ligase ligand, showing the potential to fight against leukemia with FLT3 mutations, creating a new and more effective FLT3 targeted inhibitor, which can effectively prevent or delay the development of drug resistance, reduce side effects, and provide new ideas for the limitations faced by existing treatments.

[0007] To achieve the above object, the present invention provides the following solutions:

[0008] The present invention provides a small molecule compound SorB3 for targeted degradation of FLT3 protein, wherein the chemical structural formula of the small molecule compound SorB3 is:

[0009]

[0010] The present invention also provides a method for synthesizing the small molecule compound SorB3 for targeting degradation of FLT3 protein, comprising the following steps:

[0011] (1) dissolving the E3 ligase ligand 1 in N,N-dimethylformamide, adding BOC aminopolyethylene glycol carboxyl, N,N-diisopropylethylamine and HATU, adding water after stirring and reacting, extracting with ethyl acetate to obtain an organic phase in which the target molecule is dissolved, then adding saturated brine to isolate the aqueous phase and the liquid phase, drying with anhydrous magnesium sulfate, filtering, spin drying, and purifying to obtain a white solid 1;

[0012] (2) dissolving the white solid 1 in dioxane and hydrochloric acid / dioxane, stirring and reacting, and concentrating to obtain a white solid 2;

[0013] (3) The white solid 2 was dissolved in dichloromethane, and then sorafenib, N-methylmorpholine, HOAr and EDCI were added. After stirring for reaction, the mixture was concentrated and purified to obtain the small molecule compound SorB3.

[0014] Furthermore, in step (1), the mass ratio of the E3 ligase ligand 1, BOC aminopolyethylene glycol carboxyl, N,N-diisopropylethylamine and HATU is 0.5-2:0.5-2:0.5-2:0.5-2.

[0015] Furthermore, in step (1), the stirring reaction is carried out at 25-30° C. for 2 h; the extraction is carried out at a ratio of water to ethyl acetate of 1:6; the purification is carried out by using a rapid column analyzer, and the purification conditions are: 12g Silica Flash Column, Eluent of 0~7% Ethyliacetate / Petroleumethergradient@12mL / min.

[0016] Furthermore, in step (2), the white solid 1 is dissolved in dioxane and the ratio of hydrochloric acid / dioxane is 50:100 mg:1 mL:1 mL; and the stirring reaction is carried out at 25-30°C for 16 hours.

[0017] Furthermore, in step (3), the purification is performed by prep-HPLC (water (0.05% HCl)-ACN condition).

[0018] The present invention also provides an application of the small molecule compound SorB3 for targeted degradation of FLT3 protein in the preparation of a drug for treating FLT3 mutant leukemia, wherein the drug can target and degrade FLT3 protein at the FLT3 tyrosine kinase type II target.

[0019] Furthermore, the FLT3 mutant leukemia is FLT3 mutant acute myeloid leukemia, and the FLT3 protein is FLT3-ITD cell FLT3 protein.

[0020] Furthermore, the degradation includes inhibiting and degrading FLT-3 receptor tyrosine kinase.

[0021] Furthermore, the medicine also includes pharmaceutically acceptable excipients; the dosage forms of the medicine include injections, tablets, pills and granules.

[0022] The present invention discloses the following technical effects:

[0023] The present invention uses the protein degradation targeted chimera technology (Proteolysis Targeting Chimera, PROTAC) to design and synthesize a novel FLT3 target small molecule inhibitor SorB3 using the molecular targeted inhibitor sorafenib as a precursor. It is based on the targeted inhibition ability of sorafenib on FLT3 and its good inhibitory effect on AmL resistant cell lines. A new type of targeted FLT3 small molecule inhibitor was designed and synthesized using sorafenib as a precursor through PROTAC technology. As a new type of FLT3 target inhibitor, SorB3 successfully pairs the FLT3 target protein with E3, thereby promoting the ubiquitination degradation of the target protein. After verification, it was found that SorB3 can reduce the expression level of FLT3 protein in a dose-dependent manner, can effectively inhibit the activity of FLT3 kinase, and also has a good selective inhibitory effect on FLT3-ITD expressing cells. At the same time, SorB3 has higher selectivity for FLT3 mutant AmL cells, and can effectively overcome sorafenib resistance, and still has a good inhibitory and apoptosis-inducing effect on resistant AmL cells. The toxicity to normal cells and tissues is lower than sorafenib, and it has better safety, showing the potential to fight against FLT3 mutant leukemia, providing a new direction for clinical treatment. The small molecule inhibitor SorB3 provided by the present invention is expected to solve the drug resistance problem of FLT3-TKD mutation secondary to alkali deficiency, and provides new hope for the precise targeted treatment of FLT3-ITD positive AmL patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0025] Figure 1 The synthetic route of the small molecule compound SorB3 of the present invention;

[0026] Figure 2 It is the liquid chromatography-mass spectrum of the small molecule compound SorB3 in Example 1;

[0027] Figure 3 is the HPLC chromatogram of the small molecule compound SorB3 in Example 1;

[0028] Figure 4 is the nuclear magnetic resonance image of the small molecule compound SorB3 in Example 1;

[0029] Figure 5 The diagram is a diagram of the induction of FLT3 protein degradation by the small molecule compound SorB3 in Example 1, wherein A is a WB diagram and B is a WB band grayscale analysis diagram;

[0030] Figure 6 This is a graph showing the effect of sorafenib and SorB3 on the in vitro kinase activity of FLT3 in Example 1, wherein A is sorafenib and B is SorB3;

[0031] Figure 7 This is a graph showing the inhibition of 32D / 32D 8# cell proliferation by the small molecule compound SorB3 in Example 1;

[0032] Figure 8 This is a graph showing the cell proliferation inhibition of the small molecule compound SorB3 in Example 1 on four AML cell lines, wherein A is MV4-11, B is Molm13, C is K-562, and D is HL-60;

[0033] Fig. 9 The graphs are the cell proliferation inhibition of AML / AML resistant strains and apoptosis of resistant strains by the small molecule compound SorB3 and sorafenib in Example 1, wherein A is a graph showing the cell proliferation inhibition of AML / AML resistant strains by sorafenib, B is a graph showing the cell proliferation inhibition of AML / AML resistant strains by SorB3, C is a graph showing the results of flow cytometry detection, and D is a graph showing the comparison of apoptosis rates of resistant strains by SorB3 and sorafenib;

[0034] Fig.10 These are graphs of CD34+ hematopoietic stem cell flow sorting and 293T / HSC cell proliferation inhibition, where A is a graph of CD34+ hematopoietic stem cell flow sorting, B is a graph of 293T cell proliferation inhibition, and C is a graph of HSC cell proliferation inhibition. DETAILED DESCRIPTION

[0035] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0036] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0037] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0038] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to the skilled artisan. The present invention description and examples are exemplary only.

[0039] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0040] The test methods used in the following implementations, unless otherwise specified, are all commonly used experimental methods in this field;

[0041] Unless otherwise specified, the experimental materials used in the following examples are all commonly used experimental materials in this field.

[0042] The inventors of the present invention used sorafenib as the premise of PROTAC design and selected sorafenib as the target protein molecule for PROTAC technology design. BOC amino polyethylene glycol carboxyl (BOC-NH-PEG-COOH) is used as the PROTAC linker, the N-terminal outside the active pocket is used as the binding site between the linker and sorafenib, and the E3 ligase ligand 1 ((S, R, S)-AHPC-Me hydrochloride (S, R, S)-AHPC-Me (hydrochloride)) is used as the E3 ligase ligand. Finally, the E3 ubiquitin ligase ligand 1 is connected to the molecular basis of the sorafenib docking link to complete the design of the SorB3 molecule. The synthetic route of SorB3 is shown in the figure below. Figure 1As shown, its chemical structure is:

[0043]

[0044] Example 1

[0045] 1. Experimental materials and instruments

[0046] The experimental materials used in Example 1 of the present invention are as follows, wherein the SorB3 molecule synthesis experimental reagents are shown in Table 1, the cell experimental reagents are shown in Table 2, the Western blot experimental reagents are shown in Table 3, the in vitro kinase activity experimental reagents are shown in Table 4, the cell line sources in the above experiments are shown in Table 5, the SorB3 molecule synthesis experimental equipment is shown in Table 6, and the detection experimental instruments are shown in Table 7:

[0047] Table 1 Reagents for SorB3 molecular synthesis experiments

[0048]

[0049]

[0050] Table 2 Cell experiment reagents

[0051]

[0052] Table 3 Western blot reagents

[0053]

[0054]

[0055] Table 4 In vitro kinase activity assay reagents

[0056]

[0057] Table 5 Cell line sources

[0058]

[0059] Table 6 SorB3 molecular synthesis experimental equipment

[0060]

[0061] Table 7 Testing instruments

[0062]

[0063]

[0064] 2. Test methods

[0065] 1. Synthesis of SorB3

[0066] 1) Synthesis of compound 4

[0067] Compound 2 (240 mg, 513 μmol) was dissolved in N, N-dimethylformamide (5 mL), and compound 3 (200 mg, 488 μmol) and N, N-diisopropylethylamine (189 mg, 1.47 mmol) were added. After stirring at 25-30°C for 10 minutes, HATU (223 mg, 586 μmol) was added, and the reaction solution was stirred continuously at 25-30°C for 2 hours. Water (10 mL) and ethyl acetate (10 mL*6) were added to the solution after the reaction for extraction experiments. Finally, the organic phase containing the target molecule was collected and used, and saturated brine (50 mL) was added to isolate the aqueous phase and the liquid phase, and then dried with anhydrous magnesium sulfate, filtered, and dried by spin drying. The concentrate was purified by rapid column chromatography (conditions: 12g Silica Flash Column, Eluent of 0~7%Ethylacetate / Petroleum ether gradient@12mL / min) to obtain a white solid (395mg, 68.8%yield), which is compound 4.

[0068] 2) Synthesis of compound 5

[0069] Compound 4 (395 mg, 481 μmol) was dissolved in dioxane (5 mL) and hydrochloric acid / dioxane (wherein the hydrochloric acid solution was 4 moles per liter (4M), dioxane (1,4-dioxane) was analytically pure, and the total solution volume was 5 mL. Specifically, the hydrochloric acid solution was dissolved or diluted in dioxane, the hydrochloric acid concentration was 4M, and the total volume was 5 mL), stirred at 25-30°C for 16 hours, and the reaction solution was concentrated to obtain a white solid (495 mg, crude), which was compound 5.

[0070] 3) Synthesis of SorB3

[0071] Compound 5 (100 mg, 132 μmol, HCl) was dissolved in dichloromethane (4 mL), and compound 1 (99.3 mg, 132 μmol), N-methylmorpholine (66.7 mg, 659 μmol), HOAt (5.38 mg, 39.6 μmol) and EDCI (30.3 mg, 158 μmol) were added at 0°C. The mixture was stirred at 25-30°C for 5 hours. After the reaction was complete, the reaction solution was concentrated and purified by prep-HPLC (water (0.05% HCl)-ACN condition) to obtain a white solid (22.7 mg, 14.5% yield). The white solid was SorB3. SorB3 was subjected to LC-MS analysis, HPLC analysis and NMR analysis to determine the purity of the product.

[0072] 2. Activity detection of SorB3 as a small molecule inhibitor

[0073] 1) Cell culture

[0074] Preparation of complete cell culture medium: Frozen fetal bovine serum bottles should be thawed naturally at room temperature. After confirming that they are completely thawed and free of ice crystals, they should be dispensed into 50 mL centrifuge tubes under sterile conditions. For long-term storage, they should be placed at -20°C or -80°C for use. Take out 500 mL of basic high-glucose culture medium (dulbecco's modified eagle medium, DMEM), add FBS and 1% penicillin-streptomycin solution (100×) at a ratio of 10% to prepare the total system, take out 500 mL of RIMP 1640 culture medium (Roswell Park Memorial Institute 1640), add FBS and 1% penicillin-streptomycin solution (100×) at a ratio of 10%. When culturing 32D cells (mouse IL-3-dependent cells), it is necessary to supplement IL-3 in the culture medium. The IL3 concentration of the complete culture medium is 8 ng / mL during expansion culture, and the IL3 concentration is 1 ng / mL when maintaining cell growth. Finally, mix gently to ensure that the fetal bovine serum and other components are evenly dispersed in the culture medium. Store the culture medium in a refrigerator at 4°C and avoid direct sunlight to extend its shelf life. Try to use it up within 3 weeks.

[0075] Receiving and reviving cell samples: When receiving new cell samples or frozen cells that need to be revive, first check the packaging to confirm the integrity of the sample, and record the detailed information of the cells in the experimental log. Take the frozen cell sample out of the -80℃ freezer, quickly place it in a 37℃ water bath, slightly tilt the tube and shake the cryotube at a constant speed to heat it evenly. Thawing can be completed in about 1 minute to avoid overheating. Centrifuge the thawed cells (800r, 5min) and discard the cryoprotectant. Take the preheated cell culture medium and add it to the cryotube to gently resuspend the cells. Take out the cells and transfer them to a culture dish for culture (37℃, CO2 concentration 5%).

[0076] Cell passaging: Passaging of adherent cells (human embryonic kidney cells 293T): discard all the cell culture medium in the culture dish, add 1mL of preheated 1×PBS to the dish along the side wall of the culture dish, and gently shake it back and forth to rinse the entire bottom of the culture medium to remove the residual culture medium. Discard the PBS, add an appropriate amount of trypsin to the dish along the side wall of the culture dish, rinse the flat surface of the culture dish, remove the trypsin and immediately discard it, let it stand for 10s, add 4mL of complete culture medium to terminate digestion, gently resuspend and mix, and evenly distribute the cell suspension to 2 to 4 culture dishes as needed, replenish the culture medium and place it in the incubator for culture. Passaging of suspended cells: gently resuspend the cells in the culture dish, take 1 / 2 of the cell suspension for passaging, and continue culturing after replenishing the cell culture medium.

[0077] Cryopreservation of cells:

[0078] ① Select cells that are in the logarithmic growth phase, in good condition and without contamination for cryopreservation. For adherent cells (human embryonic kidney 293T cells), follow the same digestion steps as in 4.3.1.3 cell passaging and resuspend the adherent cells into a cell suspension.

[0079] ② Add the cells to a 2 mL cell freezing tube, centrifuge (800r, 5min), and discard the culture medium supernatant.

[0080] ③ Take 1 mL of serum-free freezing solution and resuspend the cell pellet to a cell density of 3 to 5 million / mL.

[0081] Mark the samples and transfer them to -80℃ freezer for short-term storage, then transfer them to liquid nitrogen for long-term storage.

[0082] 2) Construction of 32D FLT3 overexpression cell line

[0083] The IL-3-independent 32D cell line expressing FLT3-ITD was constructed using lentiviral vector technology.

[0084] ① Add 3μg pMD2.G, 9μg psPAX2 and 12μg FLT3-ITD lentiviral expression vector with HA tag into a 1.5mL EP tube, add 633μL 2M CaCl2, mix well, and then add dropwise into 2×HBS buffer and incubate for 15min.

[0085] ② Add to 293T cells in the logarithmic growth phase, culture for 24 hours and 48 hours, collect the virus supernatant and detect the titer.

[0086] ③ Virus (MOI=5) was added to the cell culture medium of 32D cells for co-culture. After 24 hours, cells were sorted by flow cytometry, and the corresponding expression cell lines were screened by Puromycin to obtain the 32D FLT3-ITD overexpression cell line, which was marked as 32D 8#.

[0087] 3) Construction of MV4-11 drug-resistant cell line

[0088] ① Detect the IC50 of the initial MV4-11 cell line: IC50 refers to the half-inhibitory concentration. The cell line is treated with 5 concentration gradients. CCK-8 detection is performed 24h or 48h after treatment, and the inhibition curve is drawn to calculate the concentration when the inhibition rate is 50%.

[0089] ② Initial drug culture: After the cell line is cultured and expanded normally, initial culture is performed using the IC50 and IC30 values ​​of sorafenib. If the cells can be normally passaged and expanded after 1 to 2 weeks of culture, the IC50 value is selected to continue the culture.

[0090] ③ During the culture process, each generation of cells is observed morphologically under a microscope. If some cells change morphology or die during the culture process, the drug concentration needs to be reduced. If the cells still die, intermittent induction is required. After 24h to 48h of drug induction, the drug is removed and fresh culture medium is replaced to restore the cells. After 24 to 72h of recovery, drug culture is performed again. During this process, the concentration and time of drug stimulation need to be tested. If the cells grow well, the drug concentration can be gradually increased to allow the cells to acquire drug resistance as soon as possible.

[0091] ④ Drug resistance detection: IC50 was tested on the cell line after induced culture, and the drug resistance coefficient (RI) = induced cell IC50 / initial cell IC50. The MV4-11 sorafenib-resistant cell line was named (MV4-11-SR).

[0092] 4) Isolation of HSCs

[0093] ① Transfer the peripheral blood / bone marrow specimen into a 50 mL centrifuge tube (taking 10 mL of peripheral blood or bone marrow specimen as an example), add 10 mL of 1× PBS to dilute it, and mix well to obtain a total of 20 mL of specimen dilution solution.

[0094] ② Take another 50mL centrifuge tube and add 20mL of Ficoll lymphocyte separation fluid into it (determine the volume according to the amount of specimen, Ficoll lymphocyte separation fluid: specimen diluent = 1:1).

[0095] ③ Use a Pasteur pipette to slowly add the specimen diluent along the inner wall of the Ficoll lymphocyte separation fluid centrifuge tube, and try to minimize the fluctuation of the Ficoll liquid surface.

[0096] ④ Centrifuge the centrifuge tube containing the specimen diluent and Ficoll at 1500r, 18-20℃, for 30-40min.

[0097] ⑤ After centrifugation, the liquid in the tube is divided into 4 layers with clear boundaries, including plasma, buffy coat, Ficoll, and red blood cell sediment from top to bottom. Use a Pasteur pipette to draw the buffy coat cells into a 15mL centrifuge tube. The buffy coat cells mainly include mononuclear cells, platelets, and a small amount of red blood cells.

[0098] ⑥ Add 3 times the volume of PBS to the separated buffy coat cells, centrifuge at 1500r, 18-20℃ for 10min, and discard the supernatant after centrifugation.

[0099] ⑦ Lyse red blood cells: prepare 1× red blood cell lysis solution. 1× red blood cell lysis solution (5mL): 500μL red blood cell lysis solution (10×) + 4.5mL sterile ultrapure water; add appropriate amount of 1× red blood cell lysis solution to the cell sediment in the buffy coat layer, gently blow and mix, and then stand at room temperature for 15 minutes to lyse, and mix by inverting every 5 minutes; after 15 minutes, centrifuge at 1500r, 18-20℃ for 10 minutes, discard the supernatant after centrifugation, observe the color of the cell sediment, and repeat the red lysis if the red color is still obvious.

[0100] ⑧ After the red lysis is completed, add 6-8 mL PBS to the cell pellet, gently blow and mix, take 10 μL of the cell suspension for cell counting, then centrifuge at 1500r, 18-20℃, for 10min, discard the supernatant after centrifugation. Repeat once.

[0101] ⑨The final cell pellet is mononuclear cells (PBMCs / BMMCs).

[0102] CD34+ cell magnetic bead sorting: resuspend the mononuclear cell pellet with sorting buffer according to the number of cells to be sorted, mix well and place in a 5mL sterile flow tube; add 100μL / mL selection cocktail solution to the flow tube according to the volume of sorting buffer, mix gently and let stand at room temperature for 10min; when the standing time is about to end, shake the Rapid Spheres reagent in the human whole blood CD34+ positive sorting kit in advance for 30s until there are no particles. After the standing period, add 5 μL / mL of Rapid Spheres reagent to the flow tube, mix gently and let stand at room temperature for 5 minutes; add sorting buffer to 2.5 mL of the flow tube and gently blow 2 to 3 times; place the flow tube into the sorting magnet, adsorb at room temperature for 3 minutes and discard the supernatant (invert the magnet and the flow tube together for 2 to 3 seconds, do not shake or wipe dry); repeat the above two steps 4 times to make the sorted cell population purer; remove the flow tube from the magnet, resuspend the cells in cell culture medium, and the obtained cells can be directly experimented or continued to be cultured.

[0103] 5) Western blotting

[0104] ① Pretreatment of cells: Add different concentrations of 0-10 μM candidate PROTAC small molecules (SorB3) to the 32D cell line expressing FLT3-ITD. After treating the cells for 2-24 hours at different time points, the cells were rinsed and centrifuged with pre-cooled PBS.

[0105] ② Protein extraction; collect cell samples in Ep tubes, centrifuge (3000r, 5min) and discard the supernatant. Add an appropriate amount of PBS to the cell pellet to wash the cells, resuspend and mix thoroughly, then centrifuge (3000r, 5min, 4°C) and discard the supernatant. Place the cell pellet in an ice box and operate on ice throughout the process. Add an appropriate amount of protein lysis buffer (100μL RIPA, 1% PMSF, 1% protease inhibitor, 0.2% universal nuclease) according to the amount of cell pellet, resuspend the cell pellet and oscillate to mix evenly, place on ice for 15min, oscillate the oscillator for 15s and cool on ice for 3min, repeat 3 times. Centrifuge at 4°C, 12000r, centrifuge for 20-30min) to collect the protein supernatant in a new Ep tube, retain the sample to detect the protein concentration, and add SDS loading buffer to the remaining sample according to the proportion.

[0106] ③ Glue preparation: Take the preparation of a 15-hole, 1.5mm gel as an example. Take 2 15mL centrifuge tubes, add 3.5mL of separation gel A and B, 1.5mL of concentrated gel A and B, and mix them. Add 10% APS solution to the separation gel, mix well, and use a pipette to inject the separation gel into the pre-assembled gel plate. Add the separation gel liquid level to 2-3mm below the lower edge of the green card slot. After the separation gel is injected, immediately add 10% APS solution to the concentrated gel, mix well, and gently inject the concentrated gel into the upper layer of the separation gel. After the injection of the gel is completed, insert the comb into the gel plate immediately to avoid bubbles, and leave it at room temperature for 15 minutes to solidify.

[0107] ④SDS-PAGE gel electrophoresis, after the gel solidifies, assemble the electrophoresis accessories and gel, inject the electrophoresis buffer, pull out the gel comb vertically, and load the protein sample in the preset order. Start the electrophoresis immediately after loading, and stop the electrophoresis at 90V constant voltage for about 80 minutes when the bromophenol blue indicator band reaches the green line at the bottom of the electrophoresis accessories. Among them, 1x electrophoresis buffer (1L): 18.8g glycine + 3.03g Tris + 10mL 10% SDS + ultrapure water to 1L.

[0108] ⑤ After wet transfer electrophoresis, open the gel plate and cut off the upper concentrated gel and the lower bromophenol blue gel. Activate the PVDF membrane of appropriate size in methanol in advance for 10 to 20 seconds, assemble the sponge-filter paper-gel-PVDF membrane-filter paper-sponge from the negative electrode to the positive electrode into the splint, place it into the pre-assembled wet transfer tank, put an ice box into the wet transfer tank, fill it with wet transfer buffer and place it on ice. According to the size of the target protein, transfer the membrane at a constant voltage of 100V for 1 to 1.5 hours. Among them, 1x wet transfer buffer (1L): 14.4g glycine + 3.03g Tris + 200mL methanol + ultrapure water to 1L.

[0109] ⑥ Blocking: After the transfer, place the PVDF membrane in a small box, add an appropriate amount of blocking solution to completely cover the PVDF membrane, place on a shaker for 80r, block at room temperature for 1h or at 4℃ overnight. Blocking solution (100mL): 5g BSA + PBST to 100mL.

[0110] ⑦ Incubate the primary antibody: After blocking, discard the blocking solution, dilute the primary antigen solution with the blocking solution according to the dilution ratio recommended in the primary antibody instructions, pour the diluted primary antibody into the PVDF membrane box, incubate on a shaker for 80r, and incubate at room temperature for 2h or at 4℃ overnight.

[0111] ⑧ Incubate the secondary antibody: Recover the primary antibody, add an appropriate amount of PBST to the membrane washing box, place it on a shaker for 100r, wash the membrane at room temperature for 5 minutes, repeat 3 times, and replace the PBST solution each time. After the end, add the secondary antibody to the box as recommended (80r on a shaker, incubate at room temperature for 1h).

[0112] ⑨ After the incubation with the secondary antibody is completed, discard the secondary antibody, add an appropriate amount of PBST to the membrane washing box and place it on a shaker for 100r, wash the membrane at room temperature for 5 minutes, repeat 3 times, and replace the PBST solution each time. The chemiluminescent secondary antibody needs to be prepared with a color developing solution (A:B=1:1). Use a pipette to gently add the color developing solution to the membrane, and then use the near-infrared fluorescence scanning imaging system to image.

[0113] 6) In vitro kinase activity assay

[0114] ① Kinase reaction system: reaction buffer kinase buffer (1μL, 1×), MBP (1μL, 0.5μL), ATP (1μL, 250Mm) and FLT3 protein kinase-kinase buffer with a total volume of 2μL (FLT3 protein kinase can be selected from 2μL, 1μL, 0.5μL, 0.25μL, 0μL), and the total volume is 5μL.

[0115] ② Prepare SorB3 small molecule compound solutions of different concentrations (0μM, 1μM, 40μM, 200μM, 1000μM) and set up standard wells (0, 0.03, 0.07, 0.15, 0.3, 0.6, 1.2, 2.5, 5, 10μM).

[0116] ③ The kinase reaction system and the SorB3 small molecule compound were mixed and added to a 384-well plate for 6 hours, and then 5 μL of ADP-Glo ​​was added for 40 minutes to terminate the kinase reaction and deplete the remaining ATP.

[0117] ④ Add kinase detection and protect from light for 30 minutes, then detect on Cytation 5 machine. The amount of ATP and the reaction time should be such that 20-90% ATP is converted into ADP, and 30-70% ATP is converted into ADP is more preferred. This step will reduce ADP to ATP, and ATP will react with (ultra-)Glo to emit light.

[0118] ⑤ Enter the cell imaging multifunctional microplate detection system, select the microplate reader function, select a 384-well plate, do not cover it, select luciferase activity detection, select the corresponding well, adjust the fluorescence signal gain value to 200, the integration time to 1s, and collect the detection signal.

[0119] ⑥The maximum concentration of ATP can be adjusted according to the ATP concentration in the kinase reaction system, mixed with the reaction system, and a linear standard curve is fitted based on the standard sample, and the enzyme activity is calculated according to the definition of enzyme activity.

[0120] 7) Cell proliferation assay

[0121] ①32D FLT3-ITD cells, 32D cells and MV4-11, MV4-11-SR, MOLM13, HL-60, and K-562 cells were seeded in a 96-well plate, with 8000 cells per well (50 μL / well), and different concentrations of SorB3 small molecule inhibitors (50 μL / well) were added respectively. The concentration gradient was set to 100 nM, 200 nM, 400 nM, 800 nM, 1600 nM, 3200 nM, 6400 nM, 12800 nM, and 25600 nM. Three replicate wells were set for each concentration, and a blank control was set at the same time. After 72 h of culture, 10 μL of CCK-8 solution was added to each well; incubated for 2 hours, and the absorbance (OD) value of each well was measured at a wavelength of 450 nm using an enzyme reader.

[0122] ②CCK-8 test of the inhibitory ability of small molecule inhibitors on drug-resistant cell lines

[0123] MV4-11-SR cells were seeded in a 96-well plate, with 8000 cells per well (50 μL / well), and different concentrations of SorB3 small molecule inhibitors (50 μL / well) were added respectively. The concentration gradient was set to 100 nM, 200 nM, 400 nM, 800 nM, 1600 nM, 3200 nM, 6400 nM, 12800 nM, and 25600 nM. Three replicate wells were set for each concentration, and a blank control was set at the same time. After 72 h of culture, 10 μL of CCK-8 solution was added to each well; incubated for 2 hours, and the absorbance (OD) value of each well was measured at a wavelength of 450 nm using an enzyme reader.

[0124] The cell viability was calculated using the following formula:

[0125]

[0126] Among them, OD treated is the OD value of the small molecule inhibitor treatment group, OD control is the OD value of the DMSO control group, OD blank is the OD value of the blank control well containing only culture medium.

[0127] The cell survival curve was drawn with the concentration of small molecule inhibitor as the horizontal axis and the cell survival rate as the vertical axis. The dose-response curve of the small molecule inhibitor concentration and the cell survival rate was fitted using the nonlinear regression analysis function of GraphPadPrism software to calculate the half inhibitory concentration (IC50) of SorB3 on the two cells.

[0128] 8) Flow cytometry

[0129] Sorafenib and SorB3 were added to MV4-11-SR cell lines, and the concentration was set to 2μM for 24h. Annexin V-PI apoptosis detection kit was used to detect cell apoptosis. The method is briefly described as follows: the treated cells were collected in EP tubes, centrifuged at 800r / min for 5min, 1mL PBS was added to each tube, centrifuged at 1200r / min for 10min, and the supernatant was discarded. The cells were divided into three groups and resuspended in 500μL Annexin V binding buffer (containing 2.5μL Annexin V), incubated at room temperature for 15min, and then 5μL PI was added to each tube except one control, incubated in the dark for 5min, and detected by flow cytometry to detect cell apoptosis in MV4-11-SR cell lines. The data were analyzed using flowjo software and graphed using GraphPad Prism software.

[0130] 3. Test results

[0131] 1. Synthesis of small molecule inhibitors of SorB3

[0132] The HPLC-MS spectrum of SorB3 is shown in Figure 2 As shown in Figure 2, the LC-MS results show that the measured mass of SorB3 is consistent with the theoretical value; the HPLC chromatogram of SorB3 is shown in Figure 2. Figure 3 As shown in the figure, the HPLC results prove that its molecular weight is consistent with the target molecular weight, and the purity is as high as 97.5%; the NMR image of SorB3 is shown in the figure Figure 4 As shown, 1H-NMR spectrum analysis revealed 66 hydrogen signals, including hydrogen signals in aromatic and aliphatic regions, confirming that the synthesis of SorB3 was successful and the structure was correct.

[0133] 2. Activity detection of SorB3 small molecule inhibitors

[0134] 1) SorB3 degradation ability of FLT3 protein in 32D FLT3-ITD cells

[0135] The WB method was used to detect the changes in the expression level of FLT3 protein in 32D FLT3-ITD cells (i.e., 32D 8# cells) treated with different concentrations of SorB3. The WB image of SorB3-induced FLT3 protein degradation is shown in the figure below. Figure 5 As shown, Figure 5 The results showed that SorB3 could dose-dependently reduce the expression level of FLT3 protein. At concentrations of 10nM, 100nM, 1μM and 10μM, the expression levels of FLT3 protein decreased to 51.32%, 29.64%, 10.44% and 1.41% of the DMSO control group, respectively.

[0136] 2) Effect of SorB3 on the in vitro kinase activity of FLT3 protein

[0137] The absorbance signal detected by the in vitro kinase activity assay was used to calculate and evaluate the inhibitory effect of SorB3 on FLT3 kinase activity. Figure 6 As shown, the results showed that SorB3 could effectively inhibit the FLT3 kinase activity, and its IC50 value was 3.429 μM, which was comparable to the positive control drug sorafenib (IC50=0.47 μM). The above results confirmed that SorB3 could effectively inhibit the FLT3 signaling pathway, providing a molecular basis for its anti-AmL activity.

[0138] 3) The median lethal concentration of SorB3 against 32D / 32D-FLT3

[0139] The inhibitory activity of SorB3 on FLT3-ITD-expressing 32D 8 (32D 8#) and common 32D cell lines was detected by CCK-8 method. Figure 7 As shown, the results showed that the IC50 value of SorB3 for 32D FLT3-ITD cells was 3509nM, which was significantly lower than the IC50 value for ordinary 32D cells (11435nM), indicating that SorB3 has a good selective inhibitory effect on FLT3-ITD expressing cells.

[0140] 4) Effect of SorB3 on the activity of AmL cells

[0141] The inhibitory activity of SorB3 on the proliferation of four AmL cell lines (MV4-11, Molm13, K-562 and HL-60) was evaluated. The results of CCK-8 assay showed that the IC50 values ​​of SorB3 on these four cell lines were 134.8nM, 385.3nM, 1364.2nM and 1528.7nM, respectively. Figure 8 As shown, the results showed that SorB3 had the strongest inhibitory activity against MV4-11 and Molm 13 cells carrying FLT3-ITD mutations, and the IC50 values ​​were significantly lower than those of the other two FLT3 wild-type cell lines, indicating that SorB3 had a higher selectivity for FLT3 mutant AmL cells.

[0142] 5) Effect of SorB3 on the activity of drug-resistant cells

[0143] The results of CCK-8 experiments showed that the IC50 value of MV4-11-SR cells for sorafenib (8934nM) was much higher than that of the parental strain MV4-11 (52.29nM), and the IC50 value of SorB3 for MV4-11-SR cells was 2174nM, which still maintained strong inhibitory activity (such as Fig. 9 ).

[0144] Flow cytometry results (such as Fig. 9 ) further showed that after 2 μM SorB3 treatment of MV4-11-SR cells for 24 hours, the apoptosis rate reached 33.80%, which was significantly higher than that of the group treated with the same concentration of sorafenib (18.38%) and the blank control group (15.19%). The above results suggest that SorB3 can effectively overcome sorafenib resistance and still has a good inhibitory and apoptosis-inducing effect on resistant AmL cells.

[0145] 6) Safety assessment of SorB3 at the cellular level

[0146] Isolate CD34+ cells from human PBMCs / BMMCs, such as Fig.10 The CD34+HSCs content was 99.9%, indicating that the purity of the finally separated HSCs was 99.0%. The cytotoxicity of SorB3 and sorafenib on normal HSCs and 293T cells was compared by CCK-8 method. The results showed that the IC50 values ​​of SorB3 on HSCs and 293T cells were 9367nM and 6303nM, respectively, which were higher than sorafenib 4539nM and 5682nM. This indicates that SorB3 may be less toxic to normal cells and tissues than sorafenib and has better safety.

[0147] In summary, in this embodiment, a novel FLT3 target small molecule inhibitor SorB3 was designed and synthesized using the molecular targeted inhibitor sorafenib as a precursor. As a novel FLT3 target inhibitor, SorB3 successfully paired the FLT3 target protein with E3, thereby promoting the ubiquitination degradation of the target protein. It can reduce the expression level of FLT3 protein in a dose-dependent manner, can effectively inhibit the activity of FLT3 kinase, and also has a good selective inhibitory effect on FLT3-ITD expressing cells. At the same time, SorB3 has higher selectivity for FLT3 mutant AmL cells, and can effectively overcome sorafenib resistance, and still has a good inhibitory and apoptosis-inducing effect on resistant AmL cells. The toxicity to normal cells and tissues is lower than that of sorafenib, and it has better safety, showing the potential to fight against FLT3 mutant leukemia, and can effectively prevent or delay the development of drug resistance, with few side effects, providing a new direction for clinical treatment.

[0148] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A small molecule compound SorB3 that targets and degrades FLT3 protein, characterized in that: The chemical structural formula of the small molecule compound SorB3 is:

2. The method for synthesizing the small molecule compound SorB3 for targeting degradation of FLT3 protein according to claim 1, characterized in that: The following steps are involved: (1) dissolving the E3 ligase ligand 1 in N,N-dimethylformamide, adding BOC aminopolyethylene glycol carboxyl, N,N-diisopropylethylamine and HATU, adding water after stirring and reacting, extracting with ethyl acetate to obtain an organic phase in which the target molecule is dissolved, then adding saturated brine to isolate the aqueous phase and the liquid phase, drying with anhydrous magnesium sulfate, filtering, spin drying, and purifying to obtain a white solid 1; (2) dissolving the white solid 1 in dioxane and hydrochloric acid / dioxane, stirring and reacting, and concentrating to obtain a white solid 2; (3) The white solid 2 was dissolved in dichloromethane, and then sorafenib, N-methylmorpholine, HOAt and EDCI were added. After stirring for reaction, the mixture was concentrated and purified to obtain the small molecule compound SorB3.

3. The method for synthesizing the small molecule compound SorB3 for targeting degradation of FLT3 protein according to claim 2, characterized in that: In step (1), the mass ratio of the E3 ligase ligand 1, BOC amino polyethylene glycol carboxyl, N,N-diisopropylethylamine and HATU is 0.5-2:0.5-2:0.5-2:0.5-2.

4. The method for synthesizing the small molecule compound SorB3 for targeting degradation of FLT3 protein according to claim 2, characterized in that: In step (1), the stirring reaction is carried out at 25-30°C for 2h; the extraction is carried out by gradient elution, and 10mL of water and 10mL of 6 ethyl acetate are added to the solution after the reaction for extraction; the purification is carried out by rapid column purification, and the purification conditions are: 12g Silica Flash Column, Eluent of 0~7% Ethyl acetate / Petroleum ethergradient@12mL / min.

5. The method for synthesizing the small molecule compound SorB3 for targeting degradation of FLT3 protein according to claim 2, characterized in that: In step (2), the white solid 1 is dissolved in dioxane and the ratio of hydrochloric acid / dioxane is 50-100 mg:1 mL:1 mL; and the stirring reaction is carried out at 25-30° C. for 16 hours.

6. The method for synthesizing the small molecule compound SorB3 for targeted degradation of FLT3 protein according to claim 2, characterized in that: In step (3), the purification is performed by prep-HPLC (water (0.05% HCl)-ACN condition).

7. Use of the small molecule compound SorB3 for targeting degradation of FLT3 protein as claimed in claim 1 in the preparation of a drug for treating FLT3 mutant leukemia, characterized in that: The drug can target FLT3 tyrosine kinase type II targets and degrade FLT3 protein.

8. The use according to claim 7, characterized in that: The FLT3 mutant leukemia is FLT3 mutant acute myeloid leukemia, and the FLT3 protein is FLT3-ITD cell FLT3 protein.

9. The use according to claim 7, characterized in that: The degradation includes inhibiting and degrading FLT-3 receptor tyrosine kinase.

10. The use according to claim 7, characterized in that: The medicine also includes pharmaceutically acceptable excipients; the dosage form of the medicine includes injection, tablet, pill and granule.